© Reuters. The company logo for Haleon and trading information are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., July 20, 2022. REUTERS / Brendan McDermid
LONDON (Reuters) – Haleon on Tuesday said it had informed GSK and Pfizer (NYSE:) that it has denied its claim regarding litigation in the United States over the heartburn drug, Zantac.
More than 2,000 legal lawsuits related to Zantac have been filed in the United States alleging that the compound may contain carcinogens.
Zantac, originally marketed by GSK’s predecessor, was sold by a number of companies at different times, including Pfizer, Boehringer Ingelheim and Sanofi (NASDAQ 🙂 as well as a lot of generic drug manufacturers.
Haleon, which spun off as an independent company in July, comprises consumer health assets that were once owned by GSK and Pfizer.